Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 212264
Company: PRINSTON PHARMA INC
Company: PRINSTON PHARMA INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| EMPAGLIFLOZIN AND LINAGLIPTIN | EMPAGLIFLOZIN; LINAGLIPTIN | 10MG;5MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
| EMPAGLIFLOZIN AND LINAGLIPTIN | EMPAGLIFLOZIN; LINAGLIPTIN | 25MG;5MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 01/20/2022 | ORIG-1 | Tentative Approval | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212264Orig1s000TA_ltr.pdf |